Science & Research
Fitzroy Minerals Identifies Large Conductive Anomalies at Caballos Copper Project, Chile
Fitzroy Minerals reports that a MobileMT survey at its Caballos copper project in Chile has linked multiple large conductive anomalies to copper-molybdenum-gold drill intercepts, suggesting a porphyry-related hydrothermal system and potential for a district-scale mineralizing system.
Oncotelic's PDAOAI Platform Targets AI Bias in Pharma with Evidence-Interrogation Approach
Oncotelic Therapeutics' PDAOAI platform indexes over 125,000 PubMed abstracts on TGF-β signaling to generate testable hypotheses, addressing transparency and bias challenges in AI-driven drug discovery.
Study Finds Exercise and Ibuprofen May Alleviate Chemo Brain in Cancer Patients
New research suggests that exercise and the common over-the-counter drug ibuprofen can help combat cognitive decline in cancer patients undergoing chemotherapy and radiation, a condition known as chemo brain.
ARMR Sciences Advances Fentanyl Vaccine Toward Human Trials with Private Placement
ARMR Sciences Inc. completed a private placement financing led by Joseph Gunnar & Co. to advance its preventive fentanyl vaccine toward human trials, aiming to address the synthetic drug crisis.
Nicola Mining Begins 2026 Diamond Drilling at New Craigmont Copper Project, Targeting High-Grade Porphyry-Skarn Potential
Nicola Mining has launched its 2026 diamond drilling program at the New Craigmont Copper Project in British Columbia, targeting the Jotun anomaly to explore for a porphyry-skarn system, with implications for expanding copper resources near Canada's largest copper mine.
Helus Pharma Partners with TARA Mind to Boost Veteran Recruitment in Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 trial of HLP003 for major depressive disorder, aligning with a recent executive order on mental health.
Brain Health Shaped by Lifetime Mental, Physical, Environmental and Lifestyle Factors, New AHA Statement Says
A new American Heart Association scientific statement highlights that brain health is influenced by a range of factors across the entire lifespan, including mental health, sleep, environment, and social conditions, offering opportunities for early intervention to reduce the risk of stroke, cognitive decline, and dementia.
New Molecule Shows Promise for Glioblastoma Treatment, Clinical Trial Underway
Researchers at Brown University Health have identified a molecule that may alter glioblastoma treatment, with a clinical trial planning direct surgical delivery to the tumor.
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and immunotherapy while reducing side effects, with ongoing clinical trials for ovarian and colon cancers.
ESGold Corp. Launches District-Scale Survey to Unlock Full Potential of Montauban Gold-Silver Project
ESGold Corp. has expanded its ANT survey to 70 square kilometers at its Montauban project in Québec, aiming to define the full scale of a deep mineralized corridor and advance toward production.
8 Tips to Protect Your Vision as You Age, According to the National Eye Institute
The National Eye Institute offers eight actionable tips for maintaining eye health, emphasizing the importance of regular exams, healthy lifestyle choices, and managing chronic conditions to prevent vision loss.
TransCode Therapeutics Appoints Scientific Advisory Board Chair, Partners with Michigan State University to Advance RNA-Based Cancer Therapies
TransCode Therapeutics announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with Michigan State University to advance its RNA-based therapeutic pipeline, including lead candidate TTX-MC138.
GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Industry Shift to In Vivo Cancer Therapies
GeoVax highlights its gene-directed enzyme prodrug therapy Gedeptin as a potential immune-sensitizing platform that could enhance checkpoint inhibitor efficacy in solid tumors, aligning with rising industry investment in simplified in vivo cancer treatments.
Advanced Heart, Kidney and Metabolic Syndrome Linked to 30% Higher Cancer Risk, Study Finds
New research published in Circulation: Population Health and Outcomes reveals that later stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a 25-30% increased risk of cancer, highlighting the need for integrated screening.
Powermax Minerals Identifies Rare Earth Targets at Atikokan Project, Strengthening North America's Critical Mineral Supply
Powermax Minerals refines exploration at its Atikokan Rare Earth Property in Ontario, identifying priority zones through integrated geochemical and geophysical data, supporting strategic demand for domestic REE supply.
LIXTE Biotechnology Advances Precision Cancer Treatment with Novel PP2A Inhibitor
LIXTE Biotechnology is pioneering a new approach in oncology with its lead compound LB-100, which enhances chemotherapy and radiation efficacy while reducing side effects, potentially improving patient outcomes.
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.
Lakeville Clinic Reports Early Neuropathy Improvement in Patient After Two Weeks
ALIGN Integrated Health in Lakeville, Minnesota reports that a Burnsville patient showed measurable improvement in neuropathy symptoms within two weeks of starting integrative treatment, highlighting the importance of early intervention.
Canamera Energy Metals Expands Brazil Auger Drill Program as Early Rare Earth Results Show Encouraging Grades
Canamera Energy Metals Corp. expanded its auger drilling program at the Turvolândia rare earth project in Brazil to 1,200 meters after early assays, including a hole returning 3,255 ppm TREO over 13 meters, indicated potential for ion adsorption clay-style mineralization.
Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR 2026, Highlighting Potential in Gastric Cancer and Immunotherapy
Tonix Pharmaceuticals announced new preclinical data for TNX-1700 and TNX-4700 at AACR 2026, showing potential in gastric cancer and as a BTLA-targeting immunotherapy, which could expand its oncology pipeline.
Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Novel Urine Test May Predict Bladder Cancer Treatment Response
Researchers have developed a urine test that detects tumor DNA to predict residual bladder cancer after surgery and assess immunotherapy effectiveness.
American Heart Association Mourns Passing of Pioneering Cardiologist Eugene Braunwald
The American Heart Association honors the legacy of Dr. Eugene Braunwald, whose seven decades of research transformed cardiovascular medicine, and highlights his enduring influence through mentorship and the Eugene Braunwald Academic Mentorship Award.
Physical Activity May Be Safer Than Thought for Children with Certain Heart Conditions, New Statement Says
The American Heart Association's new scientific statement suggests that with proper evaluation and monitoring, physical activity can be beneficial for children with cardiomyopathies or implantable cardioverter-defibrillators, shifting away from blanket restrictions.
Soligenix's Platform Approach to Drug Development Offers Efficiency in Biopharmaceutical Innovation
Soligenix Inc. demonstrates how platform-based drug development using synthetic hypericin across multiple dermatologic conditions can streamline clinical impact and reduce redundancy in the biotech industry.
Powermax Minerals Reports Promising Rare Earth Element Findings in British Columbia
Powermax Minerals Inc. has identified significant rare earth element mineralization trends at its Cameron project in British Columbia, highlighting potential for North American critical mineral development amid growing global demand.
Loneliness Identified as Risk Factor for Degenerative Heart Valve Disease
New research reveals that loneliness, distinct from social isolation, is associated with a significantly higher risk of developing degenerative heart valve disease, suggesting it could be a modifiable risk factor with important implications for prevention and treatment strategies.
NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform
NeuroOne Medical Technologies is collaborating with the University of Minnesota to develop a brain drug delivery system that could revolutionize epilepsy treatment by delivering therapies directly to seizure sites, potentially improving efficacy while reducing side effects.
American Heart Association Awards $15 Million to Research Early Detection of Heart Valve Disease
A new $15 million research initiative led by three major medical institutions aims to transform heart valve disease care by focusing on early detection and prevention strategies for a condition affecting over 80 million people worldwide.
NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.